Communiqués Serina Therapeutics, Inc.

Actions

SER

US81751A1088

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
2,220 ^USD	-11,20%		-18,68%	+16,05%

09/09	Serina Therapeutics fait progresser l'étude d'enregistrement du SER-252 dans la maladie de Parkinson avancée vers la cohorte 2	CI
13/08	Serina Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

10/09	Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
09/09	Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2	AQ
13/08	Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
24/07	Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference	AQ
23/07	Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
22/07	Serina Therapeutics Appoints Farrell Simon to its Board of Directors	AQ
09/07	Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
30/06	Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program	AQ
22/05	Serina Therapeutics : Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi	PU
14/05	Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
07/04	Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit	AQ
02/04	Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan	AQ
25/03	Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights	AQ
24/03	Serina Therapeutics to Present at the 38th Annual Roth Conference	AQ
18/03	Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease	AQ
24/02	Serina Therapeutics : Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease	PU
19/02	Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease	AQ
03/02	Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event	AQ
30/01	Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease	AQ
29/01	Serina Therapeutics : Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease	PU
16/01	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders Equity	AQ
15/01	Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity	AQ
06/01	Serina Therapeutics : Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities	PU
18/12	Serina Therapeutics : Enable Injections Announces Regulatory Approval in Saudi Arabia for the EMPAVELI® Injector based on enFuse® Technology	PU
11/12	Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry	AQ